What type of study is this?

This is a Pre-Registered Trial study.

Inhibition of Interleukin-33 in Diabetic Kidney Disease

View Full Paper

Ask AI

Bookmark

Authors

Phase 2b trial evaluated tozorakimab's therapeutic potential in diabetic kidney disease, revealing no significant UACR reduction vs placebo.

Tozorakimab effectively inhibited interleukin-33 signaling with 95% reduction across doses administered.
The primary endpoint was urinary albumin-to-creatinine ratio change from baseline to Day 169, showing no significant difference between groups.
Double-blind methodology ensured robust comparison between the therapeutic antibody and placebo over 24 weeks.
Findings highlight the complexity of treating diabetic kidney disease and call for further studies on inflammatory biomarkers.

Hofherr et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 2b trial evaluated tozorakimab's therapeutic potential in diabetic kidney disease, revealing no significant UACR reduction vs placebo.